Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Cordyceps Capsule is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Anhui University of Chinese Medicine. It is an internal agreement formula (院内协定方) used in the treatment of interstitial lung diseases, including Idiopathic Pulmonary Fibrosis (IPF) and Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD). The formulation is based on the 'Yiqi Yangyin Huoxue method' (replenishing qi, nourishing yin, and activating blood circulation), a therapeutic principle in TCM. The capsule contains a combination of traditional Chinese medicinal ingredients, notably ginseng, notoginseng, and cordyceps, which are believed to exert their therapeutic effects through various biological pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Cordyceps Capsule.